DelveInsight’s “Peritoneal Carcinomatosis Market Insight, Epidemiology, and Market Forecast – 2040” report delivers a comprehensive analysis of the peritoneal carcinomatosis landscape, covering market dynamics, clinical development activities, and epidemiological trends. The report provides both historical and forecasted data alongside a detailed evaluation of market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The Peritoneal Carcinomatosis Treatment Market Report features real-world prescription pattern analysis, emerging drug assessments, market share evaluations, and uptake/adoption patterns for individual therapies, along with historical and projected market sizing from 2020 to 2040 across the 7MM. It further examines current treatment practices, algorithms, and unmet medical needs to identify the most compelling opportunities and assess the market’s underlying growth potential.
Request for Unlocking the Sample Page of the Peritoneal Carcinomatosis Market Report @ Peritoneal Carcinomatosis Market Outlook
Peritoneal Carcinomatosis Market Summary
The Peritoneal Carcinomatosis market is poised for significant growth as disease awareness continues to rise and more effective interventions progress through clinical development.
Key Market Facts at a Glance
- Leading Peritoneal Carcinomatosis Companies include Genelux Corporation, Oncoinvent AS, Taiho Pharmaceutical Co. Ltd., Neovii Biotech, OncoNano Medicine Inc., Novartis Pharmaceuticals, Ipsen, Lumicell Inc., Merck Sharp & Dohme LLC, Boryung Pharmaceuticals Co. Ltd., and others.
- Peritoneal carcinomatosis represents the intraperitoneal dissemination of tumors not originating from the peritoneum itself, making it the most common diffuse peritoneal disease.
- The peritoneum ranks as the second most prevalent site of metastatic spread, following the liver.
- Approximately 7 out of every 1 million individuals are diagnosed with peritoneal carcinomatosis annually.
- The disease demonstrates higher incidence rates in women, with an average age at diagnosis of approximately 60 years, and may exhibit ethnic variations, with potentially higher occurrence observed in white women compared to black women.
- Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly recognized as the standard-of-care treatment approach for eligible patients. Although most patients experience relapse following multimodal treatment, incorporating surgical intervention is believed to enhance overall survival and preserve quality of life.
- No FDA-approved drugs currently exist specifically for peritoneal carcinomatosis treatment. However, targeted therapies including bevacizumab (anti-VEGF) and PARP inhibitors are utilized in certain settings, particularly for ovarian cancers harboring BRCA mutations, and show considerable promise when combined with chemotherapy.
- Radspherin, a novel radiopharmaceutical therapy developed by Oncoinvent, represents the most notable candidate in the current development pipeline.
- In June 2025, Oncoinvent announced positive final data from the Phase I/IIa trial of Radspherin in patients with colorectal peritoneal metastases, demonstrating sustained peritoneal disease control and reinforcing the potential of this novel radiopharmaceutical approach.
- Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is an innovative minimally invasive chemotherapy technique that reduces pain and may benefit patients with peritoneal carcinomatosis when incorporated alongside systemic therapy.
Discover the complete peritoneal carcinomatosis market landscape and future projections @ Peritoneal Carcinomatosis Market Forecast
Key Factors Driving Peritoneal Carcinomatosis Market Growth
Rising Incidence of Gastrointestinal and Gynecological Cancers
Peritoneal carcinomatosis frequently develops as a secondary complication of primary malignancies, including colorectal, gastric, ovarian, and pancreatic cancers. The escalating global prevalence of these cancers is substantially contributing to market expansion as growing patient populations require advanced diagnostic and therapeutic solutions.
Advancements in Diagnostic Technologies
Enhanced imaging modalities—including advanced CT scans, MRI, and PET imaging—are facilitating earlier and more precise detection of peritoneal metastases. These technological improvements enable clinicians to identify disease at earlier stages, increasing demand for specialized treatments and accelerating market growth.
Growing Adoption of CRS and HIPEC
The combination of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy has gained significant clinical acceptance as a promising therapeutic strategy for selected peritoneal carcinomatosis patients. The expanding utilization of this approach is driving demand for specialized therapies and fueling market expansion.
Increasing Research and Development Investment
Pharmaceutical and biotechnology companies are actively channeling resources into research programs focused on developing innovative targeted therapies, immunotherapies, and novel drug delivery systems for peritoneal metastases. These initiatives are expected to enhance patient outcomes and stimulate substantial market growth.
Expanding Oncology Drug Pipelines
The ongoing development of novel oncology agents targeting metastatic cancers is reshaping the peritoneal carcinomatosis treatment landscape. A robust pipeline of investigational therapies under clinical evaluation is anticipated to introduce more effective treatment options in the foreseeable future.
Improved Healthcare Infrastructure and Cancer Care Access
The expansion of specialized cancer treatment centers, strengthened healthcare infrastructure, and improved access to oncology care in developing regions are supporting earlier diagnosis and treatment initiation, thereby contributing to sustained market growth.
Growing Awareness and Screening Programs
Increasing public awareness of cancer symptoms, early detection initiatives, and routine screening programs are helping identify cancers that may progress to peritoneal carcinomatosis at earlier, more treatable stages—expanding the eligible patient pool and boosting market demand.
Explore the key market drivers and barriers shaping the Peritoneal Carcinomatosis landscape @ Peritoneal Carcinomatosis Market Dynamics
Peritoneal Carcinomatosis Disease Overview
Peritoneal carcinomatosis is a rare form of cancer that develops within the peritoneum—the thin membrane lining the abdominal cavity. It is predominantly caused by metastatic spread from other primary malignancies, most commonly originating from the ovaries, gastrointestinal tract (including colon, stomach, and appendix), and pancreas. Established risk factors include advancing age, BRCA genetic mutations, hormone replacement therapy, obesity, endometriosis, and family history of ovarian or peritoneal cancer.
Symptoms
Clinical symptoms of peritoneal carcinomatosis typically manifest at advanced disease stages when cancer cells have proliferated significantly and begun affecting surrounding organs. Common presentations include diarrhea, constipation, nausea, abdominal swelling and pain, bloating, unexplained weight fluctuations, extreme fatigue, and loss of appetite. As the disease progresses, urinary symptoms may emerge if neighboring organs such as the bladder or ureters become involved, while shortness of breath can develop due to pressure from peritoneal fluid accumulation (ascites).
Diagnosis
Diagnosing peritoneal carcinomatosis typically requires a multimodal approach combining medical history review, physical examination, advanced imaging, and sometimes invasive procedures—owing to the disease’s diffuse spread across the peritoneal lining without forming discrete masses. Initial diagnostic workup generally includes computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET scans) to visualize tumor dissemination and ascites. Confirmatory procedures such as peritoneal washing cytology, staging laparoscopy, and tissue biopsy are frequently performed to establish definitive diagnosis and accurately assess tumor burden. Supplementary tools including tumor marker blood tests and emerging modalities like circulating tumor DNA analysis may provide additional diagnostic support. The Peritoneal Carcinomatosis Index (PCI) serves as a critical assessment tool for evaluating tumor extent and guiding treatment planning.
Country-specific diagnostic variation details are provided in the full report.
Current Treatment Landscape
Managing peritoneal carcinomatosis presents considerable therapeutic challenges, as the condition typically arises from advanced invasive cancers that have metastasized from primary sites. The primary treatment objective centers on symptom management, pain relief, and quality of life optimization.
The cornerstone of treatment involves a combination of cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and peritonectomy. CRS aims to surgically excise all visible tumor deposits from the peritoneum and affected organs, while HIPEC involves circulating heated chemotherapy directly into the abdominal cavity to eliminate residual microscopic cancer cells. This combined approach has meaningfully improved survival outcomes for selected patients, particularly those with colorectal, ovarian, gastric cancers, and other peritoneal surface malignancies.
Systemic chemotherapy utilizing platinum-based agents and taxanes is administered either before or after surgery but demonstrates limited peritoneal penetration, often leaving residual disease. Neoadjuvant chemotherapy (NACT), administered prior to surgery, helps reduce tumor volume, improving the probability of successful cytoreduction and enhancing surgical outcomes in responsive patients.
Additional treatment details are provided in the full report.
Gain comprehensive insights into peritoneal carcinomatosis treatment algorithms and emerging approaches @ Peritoneal Carcinomatosis Treatment Analysis
Peritoneal Carcinomatosis Epidemiology
The epidemiology chapter provides historical and forecasted data segmented by total cases of different cancer types associated with peritoneal carcinomatosis, total diagnosed cases, and total treated cases across the 7MM from 2020 to 2040.
Key Epidemiological Insights:
- Approximately 7 out of every 1 million individuals receive a peritoneal carcinomatosis diagnosis annually.
- An estimated 40–60% of patients undergoing curative gastrectomy followed by systemic chemotherapy experience peritoneal carcinomatosis as the sole site of cancer recurrence.
- Peritoneal carcinomatosis accounts for approximately 10% of all combined peritoneal and ovarian cancer cases.
Spotlight on Emerging Peritoneal Carcinomatosis Therapies
- Radspherin – Oncoinvent
Radspherin is an innovative alpha-emitting radioactive microparticle suspension engineered for localized treatment of metastatic cancers within body cavities. The therapy consists of an alpha-radiating microparticle suspension that is instilled directly into the targeted body cavity, enabling local radiopharmaceutical therapy without the need for systemic administration. Radspherin has received Fast Track Designation (FTD) from the FDA for treating patients with peritoneal metastases from ovarian cancer.
- Mechanism of Action:
Radspherin delivers radium-224, an alpha emitter encapsulated within biodegradable microspheres, directly into the peritoneal cavity following cytoreductive surgery. Alpha particles possess high energy but an extremely short penetration range (~50–100 μm), enabling precise tumor cell destruction while sparing adjacent healthy tissues. Upon intraperitoneal administration, Radspherin disperses throughout the peritoneal cavity where residual microscopic cancer cells persist post-surgery. The alpha radiation induces irreversible double-strand DNA breaks in cancer cells, triggering apoptosis or necrosis in areas where standard systemic chemotherapy has limited reach. This targeted approach aims to reduce peritoneal metastasis recurrence by eradicating microscopic residual disease.
Near-Term Milestones for Radspherin:
- Phase I/IIa Colorectal Cancer: Key readout expected late H1 2025
- Phase I Ovarian Cancer: 24-month maturity data targeted for H2 2025
- Phase II Ovarian Cancer: Interim readout projected for late H2 2026
- GL-ONC1 – Genelux Corporation
GL-ONC1 is a genetically engineered oncolytic virus under investigation in a Phase I/II trial for peritoneal carcinomatosis, administered via intraperitoneal infusion.
Comparison of Emerging Therapies Under Development
| Drug Name | Company | Highest Phase | Indication | Route of Administration | Mechanism of Action | Molecule Type |
| Radspherin | Oncoinvent | Phase II | Peritoneal carcinomatosis from ovarian cancer | Intraperitoneal | Ionizing radiation emitters | Microparticle |
| GL-ONC1 | Genelux | Phase I/II | Peritoneal carcinomatosis | Intraperitoneal infusion | – | Genetically engineered virus |
Note: Detailed emerging therapies assessment is provided in the full report.
Download the report to discover which therapies will reshape the Peritoneal Carcinomatosis market by 2040 @ Peritoneal Carcinomatosis Emerging Therapies
Report Scope
- Study Period: 2020–2040
- Geographies Covered: Global
- Key Companies: Genelux Corporation | Oncoinvent AS | Taiho Pharmaceutical Co. Ltd. | Neovii Biotech | OncoNano Medicine Inc. | Novartis Pharmaceuticals | Ipsen | Lumicell Inc. | Merck Sharp & Dohme LLC | Boryung Pharmaceuticals Co. Ltd. | Others
- Key Therapies: Radspherin | GL-ONC1
For the complete analysis of the Peritoneal Carcinomatosis market, pipeline activities, and future growth projections, access the full report @ Peritoneal Carcinomatosis Market Report
About DelveInsight
DelveInsight is a premier healthcare-focused market research and consulting firm dedicated to delivering high-quality market intelligence and strategic analysis that supports well-informed business decisions. Backed by a team of experienced industry specialists with deep expertise across the life sciences and healthcare sectors, DelveInsight provides customized research solutions and actionable insights to organizations worldwide. Connect with us to access accurate, real-time intelligence that positions you ahead of the growth curve.
